Download PDF
Synlett 2008(5): 702-706  
DOI: 10.1055/s-2008-1042762
LETTER
© Georg Thieme Verlag Stuttgart · New York

A Short Synthesis of Conformationally Constrained Unnatural Bicyclic Amino Acids Containing a Nitrogen Atom at the Ring Juncture: (9aR)- and (9aS)-Octahydropyrido[1,2-a]pyrazine-(3S)-carboxylic Acids (Opc)

Soon Mog So, Chang-Eun Yeom, Seong Mi Cho, Soo Young Choi, Young Keun Chung, B. Moon Kim*
Department of Chemistry, College of Natural Sciences, Seoul National University, Seoul 151-747, Korea
Fax: +82(2)8727505; e-Mail: kimbm@snu.ac.kr;
Further Information

Publication History

Received 15 November 2007
Publication Date:
12 February 2008 (online)

    Permissions and Reprints All articles of this category

Abstract

A short and efficient route to conformationally constrained amino acid analogues, (9aR)- and (9aS)-octahydropyrido[1,2-a]pyrazine-(3S)-carboxylate (Opc) has been developed. The new bicyclic amino acid derivatives can be stored and utilized as a modular unit for the construction of unnatural oligopeptides using conventional peptide coupling methods.

Key words

conformationally constrained - unnatural amino acid - bicyclic - peptidomimetic - cyclic sulfamidate

    References and Notes

  • For a review, see:
  • 1a Goodmann M. Ro S. In Burger’s Medicinal Chemistry and Drug Discovery   Vol. 1:  Wolff ME. John Wiley and Sons; New York: 1995.  p.803-861  
    CrossrefGoogle Scholar
  • 1b Gibson SE. Guillo N. Tozer MJ. Tetrahedron  1999,  55:  585 
    CrossrefGoogle Scholar
  • 1c Hruby VJ. Acc. Chem. Res.  2001,  34:  389 
    CrossrefGoogle Scholar
  • For example, see:
  • 2a Roberts NA. Martin JA. Kinchington D. Broadhurst AV. Craig JC. Duncan IB. Galpin SA. Handa BK. Kay J. Krohn A. Lambert RW. Merrett JH. Mills JS. Parkes KEB. Redshaw S. Ritchie AJ. Taylor DL. Thomas GJ. Machin PJ. Science  1990,  248:  358 
    CrossrefGoogle Scholar
  • 2b Kalish VJ. Tetlock JH. Davies JF. Kaldor SW. Dressman BA. Reich S. Pino M. Nyugen D. Appelt K. Musick L. Wu B. Bioorg. Med. Chem. Lett.  1995,  5:  727 
    CrossrefGoogle Scholar
  • 2c Ghosh AK. Hussain KA. Fidanze S. J. Org. Chem.  1997,  62:  6080 
    CrossrefGoogle Scholar
  • For example, see:
  • 3a Hunt JT. Lee VG. Leftheris K. Seizinger B. Carboni J. Mabus J. Ricca C. Yan N. Manne V. J. Med. Chem.  1996,  39:  353 
    Google Scholar
  • 3b Georg GI. Harriman GB. Ali SM. Datta A. Hepperle M. Himes RH. Bioorg. Med. Chem. Lett.  1997,  5:  115 
    Google Scholar
  • For example, see:
  • 4a Bigge CF. Wu J. Malone TC. Taylor CP. Vartanian MG. Bioorg. Med. Chem. Lett.  1993,  3:  39 
    Google Scholar
  • 4b Ho B. Crider AM. Stables JP. Eur.
    J. Med. Chem.  2001,  205 
    Google Scholar
  • For example, see:
  • 5a Thurieau C. Félétou M. Hennig P. Raimbaud E. Canet E. Fauchère J. J. Med. Chem.  1996,  39:  2095 
    CrossrefGoogle Scholar
  • 5b Mavunkel BJ. Lu Z. Goehring RR. Lu S. Chakravarty S. Perumattam J. Novotny EA. Connolly M. Valentine H. Kyle DJ. J. Med. Chem.  1996,  39:  3169 
    CrossrefGoogle Scholar
  • 6 For example, see: Shuman RT. Rothenberger RB. Campbell CS. Smith GF. Gifford-Moore DS. Gesellchen PD. J. Med. Chem.  1993,  36:  314 
    CrossrefGoogle Scholar
  • For example, see:
  • 7a Klutchko S. Blankley CJ. Fleming RW. Hinkley JM. Werner AE. Nordin I. Holmes A. Hoefle ML. Cohen DM. J. Med. Chem.  1986,  29:  1953 
    Google Scholar
  • 7b Rosenkranz RP. Hayashi CM. Lakatos I. McClelland DL. Proc. West. Pharmacol. Soc.  1989,  32:  221 
    Google Scholar
  • 8 For example, see: Steinbaugh BA. Hamilton HW. Patt WC. Rapundalo ST. Batley BA. Lunney EA. Ryan MJ. Hicks GW. Bioorg. Med. Chem. Lett.  1994,  4:  2029 
    CrossrefGoogle Scholar
  • 9 For example, see: Klutchko S. Hamby JM. Hodges JC. Bioorg. Med. Chem. Lett.  1994,  4:  57 
    CrossrefGoogle Scholar
  • 10a Katritzky AR. Rachwal S. Rachwal B. Tetrahedron  1996,  52:  15031 
    CrossrefGoogle Scholar
  • 10b Barbier D. Marazano C. Riche C. Das BC. Potier P. J. Org. Chem.  1998,  63:  1767 
    CrossrefGoogle Scholar
  • 10c Mash EA. Williams LJ. Pfeiffer SS. Tetrahedron Lett.  1997,  38:  6977 
    CrossrefGoogle Scholar
  • 10d Kametani T. The Total Synthesis of Isoquinoline Alkaloids, In The Total Synthesis of Natural Products   Vol. 3:  ApSimon J. John Wiley; New York: 1977.  p.1-272  
    CrossrefGoogle Scholar
  • 11a Kim BM. Bae SJ. So SM. Yoo HT. Chang SK. Lee JH. Kang JS. Org. Lett.  2001,  3:  2349 
    CrossrefGoogle Scholar
  • 11b Kim BM. Vacca JP. Guare JP. Hanifin CM. Michelson SR. Darke PL. Zugay JA. Emini EA. Schleif W. Lin JH. Chen I.-W. Vastag K. Ostovic D. Anderson PS. Huff JR. Bioorg. Med. Chem. Lett.  1994,  4:  2273 
    CrossrefGoogle Scholar
  • 11c Kim BM. G uare JP. Vacca JP. Michelson SR. Darke PL. Zugay JA. Emini EA. Schleif W. Lin JH. Chen I.-W. Vastag K. Anderson PS. Huff JR. Bioorg. Med. Chem. Lett.  1995,  5:  185 
    CrossrefGoogle Scholar
  • 12a Kim BM, Graham SL, Shaw AW, de Solms J, and Ciccarone T. inventors; US  5,817,678. 
  • 12b Kim BM, Shaw AW, Graham SL, de Solms JS, and Ciccarone TM. inventors; EP  0862435. 
  • 13a Baldwin JE. Spivey AC. Schofield CJ. Tetrahedron: Asymmetry  1990,  1:  881 
    CrossrefGoogle Scholar
  • 13b Ok D. Fisher MH. Wyvratt MJ. Meinke PT. Tetrahedron Lett.  1999,  40:  3831 
    CrossrefGoogle Scholar
  • 13c Cohen SB. Halcomb RL. Org. Lett.  2001,  3:  405 
    CrossrefGoogle Scholar
  • 13d Atfani M. Wei L. Lubell WD. Org. Lett.  2001,  3:  2965 
    CrossrefGoogle Scholar
  • 13e Cohen SB. Halcomb RL. J. Am. Chem. Soc.  2002,  124:  2534 
    CrossrefGoogle Scholar
  • 13f Nicolaou KC. Huang X. Snyder SA. Rao PB. Bella M. Reddy MV. Angew. Chem. Int. Ed.  2002,  41:  834 
    CrossrefGoogle Scholar
  • 13g Posakony JJ. Grierson JR. Tewson TJ. J. Org. Chem.  2002,  67:  5164 
    CrossrefGoogle Scholar
  • 13h Pound MK. Davies DL. Pilkington MPV. Sousa MM. Wallis JD. Tetrahedron Lett.  2002,  43:  1915 
    CrossrefGoogle Scholar
  • 14a Kim BM. So SM. Tetrahedron Lett.  1998,  39:  5381 
    CrossrefPubMedGoogle Scholar
  • 14b Kim BM. So SM. Tetrahedron Lett.  1999,  40:  7687 
    CrossrefPubMedGoogle Scholar
  • 14c Kim BM. Bae SJ. So SM. Yoo HT. Chang SK. Lee JH. Kang JS. Org. Lett.  2001,  3:  2349 
    CrossrefPubMedGoogle Scholar
  • 14d Kim BM. So SM. Choi HJ. Org. Lett.  2002,  4:  949 
    CrossrefPubMedGoogle Scholar
  • 15a Baldwin JE. Adlington RM. Mellor LC. Tetrahedron  1994,  50:  5049 
    CrossrefGoogle Scholar
  • 15b Augilera B. Mayoralas AF. Jaramillo C. Tetrahedron  1997,  53:  5863 
    CrossrefGoogle Scholar
  • 15c Wel L. Lubell WD. Org. Lett.  2000,  2:  2595 
    CrossrefGoogle Scholar
  • 16 Rodwell VW. Methods in Enzymology   Part B, Vol. 17:  Academic Press; New York: 1971.  p.174 
    Google Scholar
  • 17 Henry JR. Marcin LR. McIntosh C. Scola PM. Harris GD. Weinreb SM. Tetrahedron Lett.  1989,  30:  5709 
    CrossrefGoogle Scholar
  • 18a Pederson CJ. J. Am. Chem. Soc.  1967,  89:  7017 
    CrossrefGoogle Scholar
  • 18b Alexander V. Chem. Rev.  1995,  95:  273 
    CrossrefGoogle Scholar
  • 19a Sharpless KB. Kim BM. Tetrahedron Lett.  1989,  30:  655 
    CrossrefGoogle Scholar
  • 19b Okada M. Tomioka K. Tetrahedron Lett.  1994,  35:  4585 
    CrossrefGoogle Scholar
20

CCDC #660993.

21

Characterization Data for Compound 16 [α]D 27 -15.0 (c 1.1, CHCl3). 1H NMR (300 MHz, CDCl3):
δ = 0.03 (s, 6 H), 0.88 (s, 9 H), 1.28 (t, 3 H), 1.32-1.70 (m, 6 H), 2.23-2.45 (m, 1 H), 2.50-2.57 (m, 1 H), 2.64-2.76 (m, 3 H), 2.97-3.05 (m, 1 H), 3.38-3.51 (m, 2 H), 3.94 (ABq, J = 13.3 Hz, 2 H), 3.96-3.88 (m, 1 H), 4.26-4.32 (m, 2 H), 7.21-7.32 (m, 5 H). 13C NMR (75 MHz, CDCl3): δ = -5.47, 14.28, 18.21, 22.16, 25.39, 25.84, 28.20, 51.06, 52.14, 56.96, 59.58, 60.34, 62.17, 63.70, 126.86, 128.16, 128.22, 139.85, 174.46. HRMS (CI): m/z calcd for C23H41N2O3Si
[M + H]+: 421.2886; found: 421.2884.

22

Characterization Data for Compound 17 [α]D 28 -4.1 (c 1.1, CHCl3). 1H NMR (300 MHz, CDCl3): δ = 1.29 (t, 3 H), 1.37-1.71 (m, 6 H), 2.27-2.45 (m, 2 H), 2.57-2.64 (m, 1 H), 2.82-2.91 (m, 1 H), 2.98-3.05 (m, 1 H), 3.22 (br s, 2 H), 3.35-3.42 (m, 2 H), 3.67-3.76 (m, 1 H), 3.75 (ABq, J = 12.9, 2 H), 4.13-4.24 (m, 2 H), 7.22-7.32 (m, 5 H). 13C NMR (75 MHz, CDCl3): δ = 14.25, 23.71, 23.86, 27.05, 52.47, 52.74, 54.38, 59.89, 60.92, 61.95, 63.07, 127.20, 128.35, 128.42, 139.03, 174.90. HRMS (CI): m/z calcd for C18H29N2O3 [M + H]+: 321.2178; found: 321.2176.

23

Characterization Data for Compound 19 [α]D 27 -10.5 (c 1.0, CHCl3). 1H NMR (300 MHz, CDCl3):
δ = 1.12-1.29 (m, 2 H), 1.27 (t, 3 H), 1.34-1.41 (m, 1 H), 1.56-1.59 (m, 2 H), 1.65-1.68 (m, 1 H), 1.87-1.96 (m, 2 H), 2.38-2.48 (m, 2 H), 2.70-2.74 (m, 1 H), 2.90-2.97 (m, 1 H), 3.04-3.08 (m, 1 H), 3.40 (s, 1 H), 3.90 (ABq, J = 13.7, 2 H), 4.14-4.24 (m, 2 H), 7.20-7.31 (m, 5 H). 13C NMR (75 MHz, CDCl3): δ = 14.78, 24.37, 25.96, 29.91, 53.41, 56.15, 58.27, 59.35, 60.25, 60.62, 61.85, 127.30, 128.65, 129.03, 139.75, 172.83. HRMS (CI): m/z calcd for C18H27N2O2 [M + H]+: 303.2072; found: 303.2073.

24

Characterization Data for Compound 22 [α]D 11 -31.3 (c 1.00, CHCl3).1H NMR (300 MHz, CDCl3):
δ = 1.11-1.96 (m, 17 H), 2.24-2.31 (m, 1 H), 2.70-2.88 (m, 2 H), 3.17-3.24 (m, 1 H), 3.62 (d, J = 3.2 Hz, 0.25 H), 3.66 (d, J = 3.2 Hz, 0.25 H), 3.74-3.80 (m, 3.5 H), 4.53 (d, J = 4 Hz, 0.5 H), 4.70 (d, J = 4 Hz, 0.5 H). 13C NMR (75 MHz, CDCl3): δ = 24.02, 24.07, 25.67, 28.64, 28.73, 29.54, 29.56, 46.87, 47.84, 52.58, 54.38, 55.65, 55.81, 55.93, 56.17, 60.70, 60.72, 80.55, 80.60, 155.54, 155.96, 171.68, 171.98. HRMS-FAB: m/z calcd for C15H27N2O4 [M + H]+: 299.1971; found: 299.1970.

25

Characterization Data for Compound 23 [α]D 11 +23.9 (c 1.00, CHCl3). 1H NMR (300 MHz, CDCl3): δ = 1.12-1.28 (m, 2 H), 1.51-1.61 (m, 3 H), 1.72-1.98 (m, 3 H), 2.03 (s, 0.7 H), 2.14 (s, 2.3 H), 2.24 (dd, 0.75 H), 2.33 (dd, 0.25 H), 2.49-2.61 (m, 0.25 H), 2.77-2.80 (m, 0.75 H), 3.09-3.18 (m, 0.9 H), 3.24-3.38 (m, 1.2 H), 3.43-3.54 (m, 0.9 H), 3.75 (s, 2.3 H), 3.79 (s, 0.7 H), 4.22-4.23 (m, 0.08 H), 4.27-4.28 (m, 0.08 H), 4.34-4.37 (m, 0.14 H), 5.17-5.19 (m, 0.7 H). 13C NMR (75 MHz, CDCl3): δ = 21.52, 21.81, 23.98, 25.58, 25.67, 29.55, 29.62, 45.07, 49.88, 52.51, 52.76, 53.12, 55.72, 55.82, 56.04, 56.43, 57.57, 60.63, 60.98, 170.79, 171.01, 171.22. HRMS-FAB: m/z calcd for C12H21N2O3 [M + H]+: 241.1552; found: 241.1558.

26

Characterization Data for Compound 24 [α]D 11 -59.2 (c 1.00, CHCl3). 1H NMR (300 MHz, CDCl3):
δ = 1.03-1.31 (m, 2 H), 1.41-2.01 (m, 6 H), 2.12 (s, 1.2 H), 2.23 (m, 1.8 H), 2.34-2.52 (m, 2 H), 2.78-2.86 (m, 1 H), 3.03-3.15 (m, 1 H), 3.29-3.33 (m, 0.4 H), 3.44-3.48 (m, 0.4 H), 3.71-3.78 (m, 0.2 H), 4.32-4.55 (m, 2.6 H), 5.18-5.20 (m, 0.4 H), 7.05 (s, 0.4 H), 7.26-7.69 (m, 5 H), 8.46 (m, 0.6 H). 13C NMR (75 MHz, CDCl3): δ = 21.89, 21.96, 23.81, 23.94, 25.62, 25.89, 29.62, 29.74, 43.78, 43.83, 44.07, 50.02, 52.95, 55.26, 55.52, 55.735, 55.89, 57.70, 60.75, 61.26, 126.29, 127.75, 127.88, 127.91, 128.22, 129.050, 129.14, 138.39, 138.70, 169.76, 170.05, 170.51, 170.91. HRMS-FAB: m/z calcd for C18H26N3O2 [M + H]+: 316.2025; found: 316.2026.